XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Stock Short Interest Drops 36.1%

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totaling 7,172 shares, a decrease of 36.1% from the August 31st total of 11,229 shares. Based on an average trading volume of 5,743 shares, the short-interest ratio is currently 1.2 days. Currently, 0.4% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Get XTL Biopharmaceuticals alerts:

Check Out Our Latest Report on XTLB

XTL Biopharmaceuticals Stock Performance

Shares of XTL Biopharmaceuticals stock opened at $2.31 on Thursday. XTL Biopharmaceuticals has a one year low of $2.01 and a one year high of $10.28. The company has a market cap of $5.47 million, a PE ratio of -3.61 and a beta of 1.38. The business has a 50-day simple moving average of $2.61 and a 200-day simple moving average of $2.59.

XTL Biopharmaceuticals (NASDAQ:XTLB – Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of ($0.26) million for the quarter.

XTL Biopharmaceuticals Company Profile

(Get Free Report)

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is an Israel-based clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Its research activities have centered on conditions such as systemic lupus erythematosus and multiple sclerosis, where abnormal immune responses can damage healthy tissue.

The company’s development programs have included hCDR1, also known as rigerimod, an immunomodulatory peptide investigated as a potential treatment for systemic lupus erythematosus.

Featured Stories

• Five stocks we like better than XTL Biopharmaceuticals
• Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
• O’Reilly Automotive’s Stock Slump Hides a Stronger Business
• McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
• Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test

Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.